Piper Sandler analyst David Amsellem raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $94 from $80 and keeps an Overweight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Morning Movers: Under Armour sinks following second quarter earnings
- ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42
- ANI Pharmaceuticals raises FY25 adj. EPS view to $6.98-$7.35 from $6.27-$6.62
- Is ANIP a Buy, Before Earnings?
- Positive Outlook on ANI Pharmaceuticals Despite Legal Setback: Buy Rating Reaffirmed